Rosemont Pharmaceuticals Limited

Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, Yorkshire, LS11 9XE
Telephone: +44 (0)113 244 1400
Fax: +44 (0)113 246 0738
WWW: http://www.rosemontpharma.com
Customer Care direct line: +44 (0)800 919 312
Out of Hours e-mail: pharmacovigilance@rosemontpharma.com
Out of Hours e-mail: +44 (0)7836 557 879
Summary of Product Characteristics last updated on the eMC: 11/01/2010
SPC Aciclovir 200mg/5ml Oral Suspension

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 11/01/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   03-Nov-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



In section 4.4 (special warnings and precautions for use) advice in renal impairment and elderly patients has been added.
In section 4.8 (undesirable effects) a comment regarding frequency categories and incidence has been added. Anaphylaxis has been changed to 'rarely' anaphylaxis. The heading for nervous system disorders has been updated to read 'psychiatric and' nervous system disorders. Headache and dizziness have both been added as common effects. Very rare effects of agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, somnolence, encephalopathy and coma have been added. A heading for respiratory, thoracic and mediastinal disorders has been added, with dyspnoea as a rare effect. The GI symptoms listed have been updated to read commonly reported. Under skin and subcutaneous tissue disorders, pruritis, rashes (including photosensitivity) have been added as common. Uncommon effects have been updated to include urticaria. Occasional reports of hair loss has been added. Angioedema has been added as a rare event. Under renal and urinary disorders, renal pain has been added.
 
In section 10 (date of revision of the text) the date had been updated to 03-Nov-2009.

Updated on 28/07/2005 and displayed until 11/01/2010
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 26/07/2005 and displayed until 28/07/2005
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   aciclovir


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk